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Insulin degrading enzyme) glycoprotein E (gE) interacts with glycoprotein I and with insulin degrading
enzyme (IDE), which is a receptor for the virus. We found that a VZV gE deletion mutant could only be grown
in cells expressing gE. Expression of VZV gE on the surface of cells did not interfere with VZV infection. HSV
deleted for gE is impaired for cell-to-cell spread; VZV gE could not complement this activity in an HSV gE null
mutant. VZV lacking the IDE binding domain of gE grew to peak titers nearly equivalent to parental virus;
however, it was impaired for cell-to-cell spread and for infectivity with cell-free virus. VZV deleted for a
region of gE that binds glycoprotein I could not replicate in cell culture unless grown in cells expressing gE.
We conclude that the IDE binding domain is important for efﬁcient cell-to-cell spread and infectivity of cell-
free virus.
© 2009 Published by Elsevier Inc.Introduction
Varicella-zoster virus (VZV) causes chickenpox and shingles. The
virus expresses at least seven glycoproteins. Glycoprotein B (gB) binds
to cellular heparan sulfate proteoglycans (Jacquet et al., 1998), and is
likely important for entry of VZV into the cell. gC is not required for
growth of virus in vitro (Cohen and Seidel, 1994), but is critical for
replication in fetal human skin in the SCID-hu mouse (Moffat et al.,
1998). gH facilitates cell-to-cell spread of virus (Rodriquez et al.,
1993). gL acts as a chaperone for transport of gH to the cell surface
(Duus et al., 1995). gI forms a complex with gE, and while gI is not
required for replication of VZV in some cells, gI is required for VZV
replication in Vero cells, T cells, and human skin (Cohen and Nguyen,
1997; Moffat et al., 2002). gK is required for replication of VZV and
may have a role in syncytia formation (Mo et al., 1999), while gM is
important for cell-to-cell spread (Yamagishi et al., 2008).
gE is the most abundant glycoprotein on the surface of VZV-
infected cells (Montalvo et al., 1985). gE is also present in the
cytoplasm of infected cells and on the surface of virions. gE binds to
the Fc portion of human immunoglobulin (Litwin et al., 1992).
Epithelial cells expressing gE show increased cell-to-cell contact withlsevier Inc.enhanced trans-epithelial resistance (Mo et al., 2000). During
infection, gE is taken up by endocytosis from the plasma membrane
and incorporated into virions (Maresova et al., 2005). The ORF47
protein kinase phosphorylates gE, resulting in transport of endocy-
tosed gE to the trans-Golgi network (Kenyon et al., 2002). gE forms a
heterodimer with VZV gI (Kimura et al., 1997) which enhances the
ability of gE to serve as an Fc receptor (Litwin et al., 1992). The SP1
transcription factor is important for regulating expression of VZV gE
(Berarducci et al., 2007).
gE binds to insulin degrading enzyme (IDE) which serves as a
receptor for the virus (Li et al., 2006). IDE is important for infection of
cell-free VZV, and for cell-to-cell spread of the virus in vitro. A portion of
the amino terminus of gE (amino acids 32–71) is required for binding to
IDE and a regionwithin in the ﬁrst third of gE (amino acids 163–208) is
important for its ability to form a complex with gI (Li et al., 2007).
A gE mutant isolated from patients with varicella showed
enhanced cell-to-cell spread (Santos et al., 2000). While VZV deleted
for gE failed to replicate in vitro, the latter was not complemented in a
cell line, and thus it was not formally shown to be essential (Mo et al.,
2002). Viable VZV mutants could be constructed in a gE domain
(amino acids 568 to 571- AYRV) that directs the protein to the trans-
Golgi network, but not in a domain (amino acids 582 to 585, YAGL)
that mediates endocytosis of gE (Moffat et al., 2004). Deletion of
amino acids 27–51 of gE resulted in a virus that was not impaired for
growth in cell culture, deletion of amino acids 51 to 187 of gE yielded a
virus that was impaired for replication in vitro, while deletion of
271M.A. Ali et al. / Virology 386 (2009) 270–279amino acids 27–187 resulted in a virus that could not replicate in cell
culture (Berarducci et al., 2006).
We have constructed deletion mutants of VZV lacking the IDE
binding domain of gE, a gI binding domain of gE, and nearly the entire
open reading frame of gE; the latter two mutants could only be grown
in cells expressing gE. We also determine if VZV gE expressed in
mammalian cells can complement the growth of an HSV-1 gE deletion
mutant or inhibit the growth of VZV.
Results
VZV gE is required for virus replication
Cosmid VZV MstII A-68D is deleted for amino acids 1 to 469 of the
623 amino acid gE (Fig. 1). Transfection of melanoma cells with
plasmid pCMV62 and cosmids NotI A, Not IB, Mst IIA, and Mst IIB
resulted in infectious VZV 7 days later, while transfection of cells with
plasmid pCMV62 and cosmids NotI A, Not IB, Mst IIB, and Mst IIA-68D
failed to yield CPE despite multiple transfections.
Baculovirus expressing gE was constructed so that melanoma cells
could be infected and express the glycoprotein to complement a gE
deletion mutant virus. Baculo gE-RV contains gE driven by the human
CMV IE promoter. Lysates of Sf9 cells infected with Baculo gE-RV and
immunoblotted for gE did not show evidence of gE expression (Fig.
2A, lane 2). Lysates of melanoma cells infected with the virus also
failed to show expression of gE (Fig. 2A, lane 3). Since sodium
butyrate, a histone deacetylase inhibitor, enhances expression of
foreign genes expressed by baculoviruses in mammalian cells
(Condreay et al., 1999), we treated Baculo gE-RV-infected cells with
sodium butyrate, and detected gE (Fig. 2A, lane 4). Similarly, when
cells were infected with Baculo gE-RV and then infected with VZV
deleted for gE (see below) the glycoproteinwas detected (Fig. 2A, lane
7). The size of gE in cells infected with Baculo gE-RV was similar to
that of cells infected with VZV (Fig. 2A, lane 8).Fig.1. Construction of recombinant VZV deleted for gE and for the IDE and gI binding domains
unique long (UL), unique short (US) and internal repeat (IR) and terminal repeat (TR) regio
BsaWI restriction sites used in Southern blots of virion DNA are shown in cosmid MstII A. Co
(line 5). Cosmid MstIIA-68D32-71 is deleted for codons 32 to 71 which contain the IDE bin
which encode the gI binding domain of gE (line 7). (B) The structures of VZV gE, gEΔ32-71gE was present predominantly on the surface of melanoma cells
infected with VZV ROka, and on the surface and in the cytoplasm of
cells infected with Baculo gE-RV (in the absence of gI) (Fig. 2B).
Addition of butyrate to cells infected with Baculo gE-RV resulted in a
marked increase in expression of gE. Cells infected with Baculo gE-RV
and VZV deleted for gE (see below) showed gE predominantly on the
surface with some gE also in the cytoplasm.
Melanoma cells were infected with baculovirus expressing gE 1 h
before transfection. Infection of cells with Baculo gE-StuI (which
contains VZV gE driven by the baculovirus polyhedron promoter and
the CMV IE promoter) followed by transfectionwith plasmid pCMV62
and cosmids NotI A, Not IB, Mst IIB, and Mst IIA-68D resulted in
infectious VZV 11 days later in one experiment, and 20 days later in a
second experiment. Infection of melanoma cells with Baculo gE-RV
followed by transfection with pCMV62 (which expresses the IE62
protein and enhances the efﬁciency of the transfection) and the four
cosmids (including the ORF68 deletion mutant cosmid) yielded VZV
after 11 days in one experiment and 17 days in the second experiment.
Virus resulting from the ﬁrst infection with Baculo gE-RV was termed
ROka68D and was chosen for use in subsequent experiments. The
virus was passaged in cells that had been infected with Baculo gE-RV
one day prior to infection with VZV.
To verify that ROka68D had the expected genome structure, virion
DNA was cut with BamHI and Southern blotting was performed using
probes for gE. Digestion of ROka68D resulted in two bands of 2.5 and
2.1 kb, while digestion of ROka yielded bands of 4.0 and 2.1 (Fig. 3A). PCR
was performed, using primers that span the gE deletion in ROka68D, and
sequence analysis showed that ROka68Dhad the expected deletion in gE.
Immunoblotting of cells infected with Baculo gE-RV and
ROka68D using monoclonal antibody to gE yielded bands of 60 to
90 kDa (Fig. 4A). A band of 52 kDa was detected using antibody to
VZV IE4. After one passage in melanoma cells without Baculo gE-RV,
the level of gE was reduced while the amount of viral IE4 was not
diminished (Fig. 4B).of gE. (A) The prototype VZV strain Dumas genome is 124,884 bp in length (line 1), with
ns (line 2). Four cosmids encompass the VZV genome (lines 3, 4). Selected BamHI and
smid MstII A-68D is deleted for codons 1–469 of ORF68 which encodes glycoprotein E
ding domain of gE (line 6). Cosmid MstIIA-68D163-208 is deleted for codons 163–208
, and gEΔ163-208 are shown.
Fig. 2. Expression of VZV gE in cells infected with a baculovirus expression vector. (A) Expression of VZV gE in Sf9 or melanoma cells. Sf9 cells were infected with parental baculovirus
AcNPV (lane 1) or Baculo gE-RV (lane 2). Melanoma cells were infected with Baculo gE-RV (lanes 3,4) or parental baculovirus (lanes 5,6) in the absence (lanes 3,5) or presence (lanes
4,6) of sodium butyrate (buty). Melanoma cells were infected with Baculo gE-RV in the absence of butyrate followed by VZV ROka68D (lane 7) or with VZV ROka (lane 8). (B)
Immunoﬂuorescence microscopy for VZV gE in cells infected with VZV ROka, Baculo gE-RV alone, Baculo gE-RV and sodium butyrate, or Baculo gE-RV followed by ROka68D. Nuclei
were stained with DAPI.
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To verify that the deletion in ORF68 was responsible for the lack
of infectivity of ROka68D in MeWo cells, rather than a mutation at
another site in the genome, we constructed a rescued virus. MeWo
cells were cotransfected with VZV ROka68D virion DNA and a 7.5 kb
DNA fragment containing ORF68. Rescued virus was isolated byFig. 3. Southern blots of VZV virion DNAs from cells infected with gE deletion mutants.
(A) Cells were infected with ROka, gE rescued mutant (ROka68DR), or ROka68D VZV
DNA. Virion DNAwas cut with BamHI and hybridized with a probe corresponding to gE.
(B) Virion DNA from cells infected with ROka68D32-71, ROka68D163-208, or ROka was
cut with BsaWI and hybridized with a probe corresponding to a portion of gE. Markers
indicate the size of DNAs in kilobase pairs.
Fig. 4. Immunoblot of gE expression in lysates from cells infected with ROka, ROka68DR,
or ROka68D in the presence (lane 3) or absence of Baculo gE-RV (lane 4). (A) The same
lysates in panel A were probed with antibody to VZV IE4. (B).
Fig. 5. Growth of VZV gE deletion mutants. Melanoma cells were infected with VZV ROka, ROka68DR, or ROka68D (A), or ROka, ROka68D32-71, or ROkaD163-208 (B), and the titer of
virus in cells was assayed on days 0 to 5 after infection. Each value represents the average number of plaques in twowells and error bars indicate standard errors. The experiment was
performed twice and a representative result is shown.
Table 1
Plaque numbers for cells infected with baculovirus expressing VZV gE followed by
infection with VZV ROka
Baculovirus VZV source Mean plaque
number±SE
None Cell-associated virus 147±7.1
Baculo gE-RV Cell-associated virus 136±3.5
Baculo 29 Cell-associated virus 146±2.8
None Cell-free virus 61±6.7
Baculo gE-RV Cell-free virus 75±3.9
Baculo 29 Cell-free virus 41±3.2
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DNA using primers that amplify the region that spans the deletion.
After multiple cycles of plaque puriﬁcation a virus termed ROka68DR
was isolated.
Southern blotting of virion DNA from ROka68DR-infected cells
showed two bands of 4.0 and 2.1 kb similar to the pattern seen with
ROka (Fig. 3A). To verify that the rescued virus expressed gE, lysates of
melanoma cells infected with ROka68DR were prepared and an
immunoblot was performed using antibody to gE. Similar levels of gE
were detected in cells infectedwithVZVROka andROka68DR (Fig. 4A).
Growth of ROka68D and ROka68DR in cell culture
Melanoma cells were infected with ROka68D, ROka68DR, and
ROka and for the next 5 days, the titers of virus in infected cells were
determined. ROka and ROka68DR grew to similar titers in vitro, while
ROka68D was unable to replicate in melanoma cells in the absence of
Baculo gE-RV (Fig. 5A).
Expression of VZV gE in a cell line does not inhibit infection by VZV
Since cells infected with baculovirus expressing VZV gE comple-
mented the gE deletion mutant, we determined if overexpression of
gE would inhibit the growth of wild-type VZV. HSV-1 gD has been
shown to block infection with HSV-1 as evidenced by a marked
decrease in plaque number in cells expressing gD versus control cells
(Campadelli-Fiume et al., 1988; Johnson and Spear, 1989). VZV lacks a
homolog for HSV-1 gD and gE may serve a similar role in VZV. To
determine whether expression of VZV gE might block infection with
VZV, melanoma cells were infected with baculovirus expressing gE,
sodium butyrate was added at 24 h, and 1 day later the cells were
infected with cell-free or cell-associated VZV ROka. Baculovirus
expressing VZV ORF29 was used as a control. The number of plaques
in VZV-infected cells did not differ in cells infected with baculovirus
expressing VZV gE compared with cells that had been infected with
baculovirus expressing VZV ORF29 or not infected with baculovirus
(Table 1). While high level expression of gE did not inhibit the growth
VZV, it remains possible that gE needs to be complexed with gI to
interfere with VZV replication.
VZV gE cannot complement the growth of an HSV gE mutant
VZV gE and HSV gE share 30% amino acid identity and 44% amino
acid homology. Since someproteins of VZV (encoded byORFs 10, 61, and
62) can complement their corresponding HSV homologs (VP16, ICP0,
ICP4, respectively; Felser et al., 1988; Moriuchi et al., 1992; Moriuchi et
al., 1993), we askedwhether VZV gE can complement HSV gE. HSV-1 gE
null mutants are impaired for growth on human keratinocyte cell lines(Wisner et al., 2000).We infectedHaCATcells, a humankeratinocyte cell
line, with baculovirus expressing VZV gE and treated the cells with
sodium butyrate for 24 h to induce expression of VZV gE. The cells were
then infected with HSV-1 F or HSV-1 F-gEβ (a gE null mutant). The
plaque size for cells infected with HSV-1 F-gEβwas not increased in the
presence of baculovirus expressing VZV gE (Fig. 6). The failure of VZV gE
to complement the growth of the HSV gE null mutant may have been
due to the inability of VZV gE to complex with HSV gI and/or for VZV gE
to reach the plasma membrane.
Amino acids 163–208 of gE, which are required for binding to gI, are
essential for VZV replication
Amino acids 163–208 of gE are important for its ability to bind to
VZV gI (Li et al., 2007). To construct a virus lacking these codons,
melanoma cells were infected with Baculo gE-StuI and then
transfected with plasmid pCMV62 and cosmids NotI A, Not IB, Mst
IIB, and Mst IIA or MstIIA-68D163-208 (Fig. 1). Infectious VZV was
detected 20 days after transfection with MstIIA-68D163-208, and
7 days after transfection with MstIIA. Virus resulting from the gE
deletion mutant cosmid was termed ROka68D163-208. The virus was
passaged in cells that had been infected with Baculo gE-RV one day
prior to infectionwith VZV. ROka68D163-208 could not be passaged in
melanoma cells in the absence of baculovirus expressing gE, and could
not be produced in cells transfected with MstIIA-68D163-208 and the
other 3 cosmids in the absence of the baculovirus.
To verify that ROka68D163-208 had the expected genome
structure, virion DNA was cut with BsaWI and Southern blotting was
performed using a gE probe. Digestion of ROka68D163-208 resulted in
bands 1.0 and 0.8 kb, while digestion of ROka yielded bands 0.8, 0.7
and 0.5 kb (Fig. 3B). This difference in size of bands is due to the
deletion of a BsaWI site in ROka68D163-208. PCR was performed and
sequence analysis showed that ROka68D163-208 had the expected
deletion in gE. Infection of melanoma cells with ROka68D163-208
showed that the virus could not replicate in the cells (Fig. 5B).
Fig. 6. VZV gE does not complement HSV-1 lacking gE. HaCAT cells were not infected with baculovirus (columns 1,2) or infected with baculovirus expressing gE (Baculo gE-RV)
(columns 3,4) and cells were not treated (columns 1,3) or treated (columns 2,4) with sodium butyrate (buty). One day later the cells were infected with HSV-1 F or HSV-1 F-gEβ and
three days later the cells were stained with crystal violet. A representative focus of infected cells is shown in the center of each panel.
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replication in cell culture
VZE gE is predicted to be a 623 amino acid protein (Davison and
Scott, 1986) with a 22 amino acid signal sequence at its amino
terminus and a 537 amino acid extracellular domain. Amino acids 32–
71 of gE are important for its ability to bind to IDE (Li et al., 2007). To
construct a virus lacking these codons, melanoma cells were infected
with Baculo gE-StuI and then transfected with plasmid pCMV62 and
cosmids NotI A, Not IB, Mst IIB, and Mst IIA or MstIIA-68D32-71
(Fig. 1). Infectious VZV was detected 10 days after transfection with
MstIIA-68D32-71 and 7 days after transfection with MstIIA. The
resulting virus was found to replicate in the absence of baculovirus
expressing gE. Therefore, melanoma cells that had not been infected
with baculovirus expressing gEwere transfectedwith plasmid pCMV62
and cosmids NotI A, Not IB, Mst IIB, and Mst IIA or MstIIA-68D32-71.
Infectious VZV was detected 11 days after transfection with MstIIA-
68D32-71, and 7 days after transfection with MstIIA. Virus resulting
from the gE deletion mutant cosmid was termed ROka68D32-71.
To verify that ROka68D32-71 had the expected genome structure,
virion DNAwas cut with BsaWI and Southern blotting was performed
using a gE probe. Digestion of ROka68D32-71 resulted in bands of 0.8,
0.7 and 0.4 kb, while digestion of ROka yielded bands of 0.8, 0.7, andFig. 7. VZV deleted for the IDE binding domain of gE is impaired for binding to IDE. Melanoma
with antibodies to VZV gE (Chemicon International), CD46, or IDE (Covance), and immunobl
from B. Forghani) (B).0.5 kb (Fig. 3B). The difference is due to a deletion in the smaller
BsaWI fragment in ROka68D32-71. PCR was performed and sequence
analysis showed that ROka68D32-71 had the expected deletion in gE.
To verify that ROka68D32-71 is impaired for binding to IDE,
melanoma cells were infected with ROka or ROka68D32-71, and
infected cell lysates were immunoprecipitated with antibody to VZV
gE, IDE, or CD46 (a control antibody). Immunoblotting with antibody
to IDE showed that gE from cells infected with ROka bound to IDE, but
gE from cells infected ROka68D32-71 bound little IDE (Fig. 7A, lane 1
vs. 4). Similar levels of IDE were present in the immunoprecipitates
(Fig. 7A, lanes 3, 6), and as expected antibody to CD46 did not
immunoprecipitate IDE (Fig. 7A, lanes 2, 5). Adequate levels of gE
were present in cells infected with ROka68D32-71 (Fig. 7B, lane 4).
Immunoprecipitation of lysate from cells infected with ROka using
antibody to IDE showed that IDE from infected cells bound to gE (Fig.
7B, lane 3), although the amount of gE boundwas only a fraction of the
total gE that was immunoprecipitated with anti-gE Ab (Fig. 7B, lane
1). In contrast, gE was not detected in lysate from cells infected with
ROka68D32-71 and immunoprecipitated with antibody to IDE (Fig.
7B, lane 6).
Infection of melanoma cells with cell-associated ROka68D32-71
showed that the virus grew to maximum titers that were nearly as
high as those obtained for parental (ROka) VZV (Fig. 5B).cells were infected with ROka or ROka68D32-71, cells lysates were immunoprecipitated
otting was performed with antibodies to IDE-1 (Li et al., 2006) (A) or VZV gE (7A7, a gift
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cell-free virus and for cell-to-cell spread
The prior experiments studied the replication of cell-associated
ROka68D32-71. To examine the infectivity of cell-free ROka68D32-
71, melanoma cells were infected with VZV ROka-GFP and
ROka68D32-71. Since ROka68D32-71 is partially impaired for growth
in cell culture, cells were infected 1 day earlier with the gE mutant
virus than with ROka-GFP. When similar CPE was noted for both
viruses, cells were sonicated, the lysate was centrifuged, and the
supernatant was used to infect melanoma cells, while the lysate was
immunoblotted with antibodies to VZV proteins to conﬁrm that the
level of viral protein expression was comparable. Infection of
melanoma cells with cell-free ROka68D32-71 resulted in signiﬁ-
cantly fewer plaques (mean 12 plaques±4 plaques) than infection
with cell-free ROka-GFP (mean 111 plaques±13 plaques, pb0.001, T
test, Fig. 8A). Immunoblotting of lysates from cells infected with
ROka68D32-71 and ROka-GFP showed that similar levels of VZV IE4,
thymidine kinase, and glycoprotein B were expressed, but that cells
infected with ROka68D32-71 expressed less gE than cells infected
with ROka-GFP (Fig. 8B). The antibody used to detect gE recognizes
an epitope outside of the region deleted, and detects recombinant
extracellular gE (gEt) or extracellular gE lacking amino acids 32–71
(gEtΔ32-71) (Li et al., 2007) to a similar extent (Fig. 7). The
difference in the amount of gE expressed in cells infected with ROka
or ROka68D32-71 was more apparent on immunoblot with whole
cell lysate (Fig. 8B) than after immunoprecipitation with antibody toFig. 8. VZV deleted for the IDE binding domain of gE is partially impaired for cell-to-cell spre
ROka-GFP and when CPE was similar for cells infected with the two viruses, the cells were so
melanoma cells and the cells were stained with antibody to VZV gE to determine the
immunoblotting with antibody to VZV gE (Chemicon International), gB, IE4, or thymidin
ROka68D32-71 and plaque diameters were measured by microscopy. (D) Expression of gE i
with 2% paraformaldehyde, stained with monoclonal antibody to VZV gE followed by Ale
microscopy was performed.gE followed by immunoblotting with antibody to gE (Fig. 7B). The
difference might be due to a limiting amount of gE antibody used for
the immunoprecipitation or a difference in the antibodies used for
the immunoblots.
To determine if ROka68D32-71 is impaired for cell-to-cell spread,
melanoma cells were infected with ROka68D32-71 or ROka and
plaque sizes were measured. Cells infected with ROka68D32-71
showed smaller plaques (mean 0.44 mm±0.1 mm) than cells
infected with parental virus (mean 0.72 mm±0.18 mm, Fig. 8C). The
difference in the mean plaque size was statistically signiﬁcant
(pb0.001, T test).
Immunoﬂuorescence for VZV gE showed that gE was predomi-
nantly on the surface of cells infected with VZV ROka or VZV
ROka68D32-71 (Fig. 8D). Thus, the impairment of ROka68D32-71
for cell-to-cell spread or for infectivity with cell-free virus was not due
to the inability of gE to trafﬁc to the cell surface.
VZV lacking the IDE binding domain of gE is not impaired for virion
maturation or transport to the cell surface
Since ROka68D32-71 is impaired for cell-to-cell spread, we
analyzed whether the virus could trafﬁc to the surface of the cell.
Although fewer infected cells were observed for cells infected with
ROka68D32-71 than with ROka, virions in ROka68D32-71-infected
cells were detected on the surface of cells by scanning electron
microscopy similar to those in ROka-infected cells (Fig. 9, top panels).
Transmission electron microscopy showed that VZV lacking the IDEad of virus and for infectivity. (A) Melanoma cells were infected with ROka68D32-71 or
nicated and centrifuged. The supernatant, containing cell-free virus, was used to infect
number of virus-infected foci. (B) The pellet from the centrifugation was used for
e kinase (TK). (C) Melanoma cells were infected with cell-associated VZV ROka or
n cells infected with ROka or ROka68D32-71. Infected or mock infected cells were ﬁxed
xa Fluor 488 goat anti-mouse antibody and DAPI, and confocal immunoﬂuorescence
Fig. 9. VZV deleted for the IDE binding domain of gE trafﬁcs to the cell surface. Melanoma cells were infected with VZV ROka or ROka68D32-71, cells were ﬁxed as described in
Materials and methods, and scanning electron microscopy (SEM) or transmission electron microscopy (TEM) was performed. Arrows indicate virions and bars are 400 nm.
276 M.A. Ali et al. / Virology 386 (2009) 270–279binding domain was not impaired for virion maturation or transport
to the cell surface (Fig. 9, bottom panels).
Discussion
We have found that gE and its gI binding domain are required for
VZV replication, while the IDE binding domain of gE is not essential.
We used baculovirus expressing VZV gE to complement the growth of
a VZV gE deletion mutant. While a prior experiment using a cell line
expressing VZV gE from its homologous promoter resulted in
complementation of a VZV point mutation (Moffat et al., 2004), the
authors did not show that gE was expressed on the surface of the cells.
We found that baculovirus expression of gE from the human CMV IE
promoter resulted in expression of the glycoprotein in the cytoplasm
and on the plasma membrane, especially in the presence of sodium
butyrate or with infection by the VZV gE deletion mutant (Fig. 2B).
Constitutive expression of gE may be toxic to cells (Litwin et al., 1992),
as has been reported for other herpesvirus glycoproteins (Friedman et
al., 1989: Tikoo et al., 1990). Since gE expression was not detected in
insect cells infectedwith baculovirus in the absence of butyrate or VZV
(Fig. 2A), the baculovirus system should be useful for expression of
other VZV glycoproteins in mammalian cells for complementation
studies.
VZV gE shares many of the properties of HSV gD. Both proteins
bind to cellular receptors for their respective viruses (Cocchi et al.,
1998; Geraghty et al., 1998; Li et al., 2006; Montgomery et al., 1996),
both are essential for virus replication (Feenstra et al., 1990), and both
are located in the unique short region of their genomes. Prior studies
showed that cell lines expressing HSV-1 gD interfere with HSV-1
infection (Campadelli-Fiume et al., 1988; Johnson and Spear, 1989).
Infection of these cell lines with HSV-1 failed to induce formation of
plaques even with an inoculum of 106 PFU, and HSV-1 protein
synthesis was markedly diminished in the cell lines (Johnson and
Spear, 1989). In contrast, we found no evidence for inhibition of VZV
infection in cells that had been infected with baculovirus expressing
gE (Table 1). This effect was seen for infection with either cell-
associated or cell-free VZV.While a prior paper also showed that a cell
line expressing VZV gE from its endogenous promoter did not inhibit
the growth of VZV (Moffat et al., 2004), the authors did not show thatVZV gE was expressed on the surface of the cell line. The inhibition of
HSV-1 infection by cells expressing gD has been postulated to prevent
superinfection of the cells, and help allow progeny virus to escape
from infected cells (Johnson and Spear, 1989). It is interesting to note
that virtually no infectious cell-free virus is released from VZV-
infected cells in vitro; therefore, the inability of VZV gE to block VZV
infection or reinfection might contribute to the inability of cultured
cells to release infectious cell-free VZV into the supernatant. In
addition, HSV does not result in marked syncytia formation in vitro,
while VZV-infected cells form large syncytia. Since HSV gD blocks HSV
superinfection, it might limit the degree of virus-infected cell fusion
and perhaps cell-to-cell fusion that occurs in vitro (Johnson and Spear,
1989). In contrast the inability of gE to block VZV infection may favor
virus–cell and cell–cell fusion resulting in formation of large syncytia.
Thus while VZV gE and HSV gD bind to cellular receptors, there are
likely important biological differences in how the molecules interact
with their receptors on cells.
VZV gE did not complement the growth of an HSV-1 gE null
mutant. While VZV gE is essential for VZV replication, HSV-1 gE is not
required for virus entry and replication, but is important for sorting
nascent virions to cell junctions and is essential for efﬁcient cell-to-
cell spread of HSV-1 (Collins and Johnson, 2003; Dingwell and
Johnoson, 1998; Polcicova et al., 2005). Alignment of VZV gE with
HSV-1 gE shows that amino acids 337 to 574 of VZV share 31% identity
and 45% homology with amino acids 220 to 454 of HSV-1. Thus it was
possible that VZV gEmight complement HSV-1 gE. The failure of VZV gE
to complement HSV-1 gEmay be due to several mechanisms. First, VZV
gE might not interact with HSV-1 gI properly. Since VZV gI is important
for proper maturation and cycling of VZV gE between the Golgi
apparatus and the cell surface (Mo et al., 2002; Olson and Grose, 1998),
HSV-1 gI might not be able to substitute for VZV gI. Second, the VZV
ORF47 protein kinase is required for phosphorylation of gE, localization
of gE to the Golgi apparatus, and for normal cell-to-cell spread of the
virus in infected cells (Kenyon et al., 2002). It is unknown whether the
HSVUL13 protein kinase, the homolog of VZV ORF47, can phosphorylate
VZV gE properly. Third, the interaction of VZV gE, but not HSV-1 gE,
with IDE (Li et al., 2006) could interfere with HSV-1 replication.
We found that amino acids 163–208 of VZV gE, which are required
for its interaction with gI (Li et al., 2007), are essential for virus
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VZV gE partially impaired the growth of the virus in cell culture,
reduced cell-to-cell spread, and resulted in fewer numbers of
intracellular and extracellular viral particles by electron microscopy.
Taken together with our results, these experiments indicate that
amino acids 188–208 of gE are likely required for VZV replication.
While the loss of a gI binding domain may be important for proper gE
maturation and localization, or for gE to form a complexwith gI so that
gE is fully functional, the observation that gI is not essential for VZV
replication in cell culture (Cohen and Nguyen, 1997; Mallory et al.,
1997) suggests that this region of gE may have other activities, or that
it could have a critical role for the proper conformation of the
glycoprotein.
Amino acids 32–71 of VZV gE were not essential for virus
replication. Deletion of this region resulted in peak titers that were
nearly as high as those obtained with ROka. This is consistent with the
ﬁnding from electron microscopy studies in which ROka68D32-71
showed normal maturation and transport to the cell surface. In
contrast, VZV deleted in this region was partially impaired for cell-to-
cell spread and for infectivity with cell-free virus. Amino acids 32–71
of gE are required for binding IDE, a cellular receptor for the virus (Li et
al., 2006). Inhibition of IDE activity using anti-IDE antibody or siRNA
speciﬁc for IDE reduced cell-to-cell spread of virus and blocked virus
infectivity by 30–70%. The reduction in infectivity seen with cell-free
ROka68D32-71 when compared with ROka was 70–90% (Fig. 8A),
which suggests that this region of gE may have other activities besides
interactionwith IDE. For example, ROka68D32-71 displayed a reduced
level of gE expression.
Transmission and scanning electron microscopy of cells infected
with VZV lacking the IDE binding domain of gE showed no
impairment in virion maturation or transport to the cell surface.
Bacitracin inhibits IDE activity (Bennett et al., 2003), blocks IDE-gE
complex formation, inhibits VZV infectivity of cell-free virus, and
reduces cell-to-cell spread of virus (Li et al., 2006). Bacitracin
treatment of VZV-infected melanoma cells had no effect on nucleo-
capsid formation, virus maturation, or transport of virions to the cell
surface. Thus, the failure to observe differences in virus maturation or
trafﬁcking by electron microscopy in cells infected with VZV deleted
for the IDE binding domain of gE is consistent with the earlier
observations of virus-infected cells treated with bacitracin.
In summary we have shown that deletion of the IDE binding
domain of gE in VZV results in a mutant that is impaired cell-to-cell
spread and infectivity by cell-free virus. Unlike HSV-1 gE, VZV gE is
essential for virus replication. Cells expressing VZV gE complement a
VZV deletion mutant, but not an HSV-1 gE mutant. Unlike HSV-1 gD,
VZV gE does not inhibit VZV infection. These studies continue to
demonstrate the differences between HSV and VZV and emphasize
the need for further studies of VZV.
Materials and methods
Cells and viruses
Human melanoma (Mewo) cells were used for transfections and
VZV propagation. Sf9 (Spodoptera frugiperda) insect cells were used to
grow baculovirus. Two baculoviruses expressing VZV gE were
constructed. A 1.9 kb StuI–KpnI fragment which contains the ORF68
gene and its native polyadenylation sitewas ampliﬁed by PCR from the
Oka strain of VZV and inserted into the corresponding sites of plasmid
pAc-CMV (Zhou et al., 2000). The resulting plasmid pAc-CMV-gE-StuI
contains the baculovirus polyhedrin promoter and the human
immediate-early (IE) cytomegalovirus (CMV) promoter driving gE. A
second plasmid was constructed by cutting plasmid pAc-CMV-gE-StuI
with XhoI, blunting the ends with Klenow, cutting the plasmid with
KpnI, and inserting the 2.7 kb XhoI–KpnI fragment containing the IE
CMV promoter and the ORF68 gene into the EcoRV-KpnI site ofplasmid pAc-CMV. This plasmid, pAc-CMV-gE-RV, has only the human
IE CMV promoter driving gE. Recombinant baculoviruses were
constructed by cotransfecting Sf9 cells with BaculoGold-linearized
baculovirus DNA (BD Biosciences, San Diego, CA) and either pAc-CMV-
gE-StuI or pAc-CMV-gE-RV. The resulting viruses, Baculo gE-StuI or
Baculo gE-RV, were concentrated by centrifugation at 8800 ×g for 2 h
and resuspended in phosphate-buffered saline containing 1% fetal
bovine serum. Baculovirus expressing VZV ORF29 was described
previously (Cohen et al., 2007).
VZV ROka was derived by transfection from cosmids correspond-
ing to the Oka vaccine strain and ROka-GFP, expressing the green
ﬂuorescence protein, has been described previously (Li et al., 2006).
HSV-1 F and HSV-1 F-gEβ, a gE-null mutant derived from strain F,
were previously described (Dingwell et al., 1994).
VZV cosmids and transfections
Cosmids NotI A, Not IB, Mst IIA, and Mst IIB are derived from the
vaccine Oka strain of VZV and encompass the whole genome (Fig. 1).
VZV ORF68, which encodes gE, is located at VZV nucleotides 115,808
to 117,676 (Davison and Scott, 1986). To produce VZV deleted for
ORF68, cosmid Mst IIA was cut with AvrII and SgrAI which cut at VZV
nucleotides 112,853 and 117,355 and cloned into plasmid pGEM2 into
which AvrII and SgrAI linkers had been inserted. The latter plasmid
was then cut with AvaI which cuts at VZV nucleotides 115,761,116,648,
and 117,218 and the large fragment was blunted with the Klenow
fragment of E. coli DNA polymerase and ligated to a double stranded
oligonucleotide (TAGCTAGGCGCGCCTAGCTA). The latter contains stop
codons in all three open reading frames and an AscI linker. The
resulting plasmid was cut with AvrII and SgrAI and inserted in place of
the wild-type sequence into cosmidMst IIA. The resulting cosmid, Mst
IIA-68D, has a deletion that begins 49 base pairs upstream of ORF68
and continues to codon 469.
Melanoma cells were transfected with plasmid pCMV62 and VZV
cosmids that had been linearized using MstII or NotI as described
previously (Cohen and Nguyen, 1997). Cells were treated with trypsin
and passaged once a week.
To rescue the ORF68 deletion mutant virus, cosmid MstII Awas cut
with SnaBI which cuts at 115,808 and 117,676 and the 7.5 kb fragment
was gel puriﬁed. Melanoma cells were transfected with the 7.5 kb
fragment containing ORF68, virion DNA from the ORF68 deletion
mutant, and plasmid pCMV62. After CPE was observed, infected cells
were sonicated to prepare cell-free virus, and centrifugation was
performed to isolate virus from insoluble debris. Serial dilutions of the
supernatant were used to infect melanoma cells. Multiple cycles of
sonication and serial dilution were performed to obtain plaque
puriﬁed rescued virus.
Cosmids deleted for the IDE or the gI binding domains of gE (Li
et al., 2007) were constructed. First plasmid pUC19 was linearized
with Pfo I, blunt ended with the Klenow fragment of E. coli DNA
polymerase I (New England BioLabs, Beverly, MA), and ligated to itself.
The resulting plasmid was cut with Sma I and a double stranded
oligonucleotide, derived from annealing 5′-CTAGGCGCGTCCCGGATC-
TAGACACCGGCG-3′ and its complementary sequence 5′-CGCCGGTG-
TCTAGATCCGGGACGCGCCTAG-3′ together was inserted into the Sma I
site. This results in insertion of Avr II, Pfo I and SgrA I sites into pUC19.
A 268 bp Pfo I–Acl I fragment containing a portion of the gE gene was
obtained by PCR using primers 5′-CTAGCAACGATTCGCGAAG-3′ and
5′-AATCATCGTATCGCAAGACGG-3′, VZV cosmid MstII A as a template,
and PfuUltra high-ﬁdelity DNA polymerase (Strategene, La Jolla, CA).
The PCR product was digested with Pfo I and Acl I and used in a three
fragment ligation with (a) the modiﬁed pUC19 plasmid described
above that had been digested with Pfo I–SgrAI and treated with
alkaline phosphatase, and (b) the Acl I–SgrA I fragment from plasmid
gEtΔ32-71 (1662 bp fragment) or gEtΔ163-208 (1641 bp fragment)
which have mutated gE sequences (Li et al., 2007). The resulting
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gEtΔ163-208. The latter two plasmids were each digested with Pfo I
and SgrA 1 and a 1.6 kb fragment containing the gE mutant sequences
from each was used in two separate three fragment ligation reactions
with (a) the modiﬁed pUC19 plasmid described above that had been
digested with Avr II and SgrA I and treated with alkaline phosphatase,
and (b) a 2.8 kb Avr II-Pfo I fragment from VZV cosmid MstII A to yield
plasmids pAvrII-SgrA-gEtΔ32-71 and pAvrII-SgrAI-gEtΔ163-208.
Finally, the latter two plasmids were each digested with AvrII and
SgrAI and a 4.5 kb fragment containing the gE mutant sequences from
each was separately ligated to the 35.4 kb Avr II-SgrA I fragment of
VZV cosmid MstII A to yield cosmids VZV MstIIA-68D32-71 and
MstIIA-68D163-208 which are deleted for the IDE and gI binding
domains of gE, respectively (Fig. 1).
Southern blotting, sequence analysis, immunoblotting,
and immunoprecipitations
Virion DNA was prepared from nucleocapsids, cut with BamHI or
BsaWI, separated on 0.8% agarose gels, transferred to nylon mem-
branes and hybridized with [32P]dCTP radiolabeled probes corre-
sponding to ORF68.
Sequence analysis of cells infected with ORF68 deletion mutants
was performed by PCR ampliﬁcation of the regions surrounding the
deletions. Primers 5′-AGCAACGATTCGCGAAGAATCC-3′ (correspond-
ing to VZV nucleotides 115,503–115,524) and 5′-CTTGGAGTCCCAA-
GAACCTAC-3′ (corresponding to nucleotides 117,802 to 117,822) were
used to amplify DNA in virus infected cells derived from cosmids VZV
Mst IIA-68D, MstIIA-68D32-71, and MstIIA-68D163-208.
Cell lysates of virus-infected cells were separated on SDS-PAGE
gels, transferred to nitrocellulose membranes, blocked with milk, and
incubated with murine monoclonal antibody to VZV gE (Chemicon
International, Temcula, Calif.), VZV glycoprotein B (Biodesign, Saco,
ME), IE4 (Moriuchi et al., 1995), or thymidine kinase (a gift from
Christine Talarico) followed by horseradish peroxidase-conjugated
anti-mouse antibody and developed using enhanced chemilumines-
cence (Pierce Chemical Co., Rockford, Ill.).
Cells lysates were prepared from VZV-infected cells in lysis buffer
(Li et al., 2006), and antibodies to VZV gE (Chemicon International,
Temecula, CA and a gift from Bagher Forghani, California State
Department of Health Services, Berkeley, CA), CD46 (Immunotech,
Marseille Cedex, France) or IDE (Covance, Berkeley, CA) were added to
the lysates with protein A. The immune complexes were fractionated
on SDS polyacrylamide gels and immunoblotted with rabbit antibody
to IDE-1 (Li et al., 2006) or mouse antibody to gE, followed by
horseradish peroxidase-conjugated rabbit or mouse antibody, and
enhanced chemiluminescence.
Virus growth analysis, cell-free virus preparation,
and immunoﬂuorescence
Virus growth was analyzed by infecting 25 cm2 ﬂasks with about
200 PFU of virus, and each day thereafter for ﬁve consecutive days two
ﬂasks for each virus were treated with trypsin and serial dilutions
were used to infect melanoma cells. One week later the cells were
ﬁxed and stained with crystal violet and plaques were counted.
Cell-free VZV was prepared by scraping ﬂasks of VZV-infected cells
in SPGC (10% fetal bovine serum, 0.1% sodium glutamate, 5% sucrose in
PBS), sonicating the lysate, and centrifuging the lysate at 1240 ×g for
10min at 4 °C. The supernatant was used to infect melanoma cells and
the pellet was used for immunoblotting.
Immunoﬂuorescence studies of gE were performed by infecting
cells with baculovirus expressing gE and 24 h later treating the cells
with 5mM sodiumbutyrate. One day later the cells were infectedwith
VZV and two days later the cells were ﬁxed with 2% paraformaldehyde
for 5min and stainedwithmonoclonal antibody to VZV gE (Chemicon,Temecula, CA) followed by Alexa Fluor 488 goat anti-mouse antibody
(Invitrogen, Carlsbad, CA), mounted with ProLong Gold antifade
reagent with DAPI (Invitrogen), and visualized by confocal immuno-
ﬂuorescence microscopy.
Scanning electron microscopy
VZV-infected cells grown on silicon chips (Ted Pella, Redding, CA)
and were ﬁxed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate
buffer, then in 1% tannic acid, and then overnight at 4 °C with 0.1%
uranyl acetate and 4% paraformaldehyde. Specimens were rehydrated
with a graded ethanol series, critical point dried under CO2 in a Bal-Tec
model cpd 030 Drier (Balzers, Liechtenstein), mounted on aluminum
studs and sputter coated with 30 Å of iridium in a model IBS/e ion
beam sputterer (South Bay Technology, Inc, San Clemente, CA) prior to
viewing at 5 kV in a Hitachi S-5200 in-lens scanning electron
microscope (Hitachi, Tokyo, Japan).
Transmission electron microscopy
VZV-infected cells were grown on thermanox coverslips (Nalge
Nunc International, Rochester, NY) and ﬁxed overnight at 4°C with
2.5% glutaraldehyde, 4% paraformaldehyde, and 0.1 M sodium
cacodylate buffer, pH 7.4. Samples were post ﬁxed 1 h with 0.5%
osmium tetroxide/0.8% potassium ferricyanide followed by 1 h in 1%
tannic acid, overnight with 1% uranyl acetate at 4°C, and dehydration
with a graded ethanol series, prior to embedding in Spurr's resin. Thin
sections were cut with an RMC MT-7000 ultramicrotome (Ventana,
Tucson, AZ), stained with 1% uranyl acetate and Reynold's lead citrate
prior to viewing at 80 kV on a Hitachi H-7500 transmission electron
microscope (Hitachi, Tokyo, Japan). Digital images were acquiredwith
a bottom mount AMT digital camera system (AMT, Chazy, NY).
Note added in proof
Since this manuscript was submitted, Berarducci et al. (J Virol.
2009;83:228–40) showed that deletion of amino acids 208–236 of
VZV gE abolishes binding of gE to gI and reduces cell-to-cell spread of
virus, but still allows VZV entry and replication in vitro.
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